Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Infectious Disease Information》 2009-06
Add to Favorite Get Latest Update

Research progress of AIDS vaccine

Liu Yong,Shao Yiming National Center for AIDS/STD Control and Prevention,China CDC,Beijing 100050,China  
AIDS vaccine research has encountered obstacles and setbacks. After the failure of first generation gp120 based protein vaccine candidate AIDSVAX in the phase Ⅲ clinical trials in Europe,America and Thailand,Merck's adenovirus vector-based second generation T cell vaccine did not provide protective immunity,but showed higher risk of HIV infection in particular subgroups of vaccinees. Despite all these defeats,scientists have been putting forward novel vaccine strategies such as immunogen screening and structure-based immunogen design. Subsequently after 25 years of research efforts,the AIDSVAX B/E prime-ALVAC-HIV boost regimen has shown partial protection in the phaseⅢ trials concluded in Thailand. The confidence for a successful AIDS vaccine has regained.
【Fund】: 国家“十一五”科技重大专项(2008ZX1001-1010)
【CateGory Index】: R392.1
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved